We recently reported the cross-neutralizing potential of two anti-CD4bs scFv monoclonals (D11 and 1F6) and one N332 V3-glycan directed scFv monoclonal (C11) identified from a human recombinant phage display library constructed from the PBMCs of HIV-1 sybtype C-infected adult cross-neutralizers. The CD4bs directed D11 scFv demonstrated 66% neutralization breadth and neutralized 33/50 viruses of different HIV-1 subtypes (43). In a recently conducted study, we observed the relative resistance of pediatric HIV-1 primary isolates to the existing bnAbs isolated from adults (33). HIV-1-infected children below the age of 2 if untreated, progress to AIDS, due to the immaturity of the immune system and limited exposure to diverse pathogens. Of late, however, cnAbs have been isolated from HIV-1 infected infants (31), providing us the impetus to generate a human recombinant scFv phage library and identify cross neutralizing CD4bs directed scFvs, using PBMCs from select pediatric cross-neutralizers. During the course of chronic infection, there is increase in breadth of the cnAbs induced by the diverse antigenicity of the circulating virus quasi-species (68–70). Our recent study on chronically infected children have also shown the presence of V1V2, V3, and CD4bs specific plasma antibodies in children, suggesting the development of bnAbs targeting multiple epitopes on HIV-1 envelope in these infected children (38).